Sareum (#SAR) new Nomad and co-broker - PLACING AHOY!
- 2015-03-16 00:15:00
The daily chart of perennial share issuer Sareum (SAR) shows that the fall in the share price since the February breakdown has been an intense one. Fear not: there is worse to come.
AIM listed biotech Sareum (SAR) has announced “Preclinical Development Candidate Selected for Aurora+FLT3 Inhibitor Programme”. As reported in February 2013, recent studies carried out by Sareum sought to differentiate the two most promising programme compounds. Whilst both molecules demonstrate similar efficacy in disease models, the preclinical candidate shows (according to the company) clear benefits in safety models and predicted human exposure, based on a number of in vitro assays.



